01 / THE ARGUMENT
A financed product still requires a functioning pathway
Cell and gene therapy creates a distinctive executive problem: a potentially transformative intervention has to cross clinical, operational and financial boundaries before its promise can become an observed outcome. A coverage decision does not reserve a treatment slot, arrange travel or ensure that follow-up data will be available when a rebate becomes due. My thesis is that readiness should be assessed at the level of the complete care pathway, with one accountable owner for each unresolved dependency.
CMS's CGT Access Model initially focuses on Medicaid access to sickle cell gene therapies. States joined between January 2025 and January 2026. The page updated September 30, 2026 describes negotiated discounts and outcomes-based rebates. Its objectives remain hypotheses under evaluation, rather than established improvements in access, outcomes or costs. [1]
02 / THE ARGUMENT
The financing instrument cannot replace the evidence system
Ossandon and colleagues' 2024 scoping review included ten publications from 279 identified records. It maps subscription, outcomes-based and amortization approaches and identifies implementation barriers including informatics, accessible endpoints, legal conditions and administration. The review is a useful map of mechanisms and obstacles, with a literature search ending in February 2023. It does not demonstrate that one financing structure outperforms another or solves present-day US access. [2]
My proposed decision sequence begins with the obligation that can actually be measured. The payer, manufacturer and clinical team should specify the eligible population, covered services, outcome definition, observation window, source of evidence and dispute process. A longer payment schedule changes timing; a performance rebate changes some risk allocation. Neither mechanically improves clinical effectiveness. Financial modeling should distinguish cash flow, total expected expenditure and uncertainty rather than describe every mechanism as a saving.
03 / THE ARGUMENT
Treatment-center capacity and household capacity belong in the same plan
CMS describes an extended inpatient stay and additional visits in the sickle cell pathway. Manufacturers must fund defined fertility-preservation services and certain related travel and lodging supports. Providers deliver care and submit data, while formal participation belongs to states and manufacturers. These requirements make coordination central to implementation. [1]
I would build a readiness register that follows each clinically assessed patient from referral through specialist review, authorization, appropriate counseling, scheduled care and follow-up. The register should identify the accountable party, outstanding prerequisite and next review date. Social work and patient navigation should be visible alongside transplant capacity and finance. Any automated reminder or missing-document detection should support professional review. It should never decide clinical eligibility or infer that a family can absorb an unresolved practical burden.
04 / THE ARGUMENT
Commercial durability is part of the access question
In Nature Medicine, Mackall and colleagues describe market failure around pediatric cell and gene therapies and propose an organization to advance development and commercialization with academic manufacturing partners. Their Perspective identifies a structural problem and a proposed response; it does not evaluate a deployed solution. [3] On February 24, 2026, Fierce Pharma reported BioMarin's decision to withdraw Roctavian after unsuccessful divestiture efforts. This is a specific commercial event, not a clinical verdict on the entire modality. [4]
My implication for executive diligence is to include continuity scenarios. A care program should know who retains follow-up responsibility if a sponsor changes strategy, how records remain accessible, and which contractual duties survive an organizational transition. A manufacturer should evaluate the economic viability of the delivery network as well as demand generation. A center should test its exposure to variable referrals and delayed collections before adding specialized fixed capacity. The pathway is more durable when those responsibilities are negotiated before expansion.
05 / THE ARGUMENT
The board should approve capacity and liquidity against completed-care evidence
I would stage investment around verified readiness. An initial phase should validate referral quality, contractual access and the center's capacity to complete the pathway. A second phase should measure actual time to treatment, reasons for noncompletion, uncompensated coordination expense and the completeness of outcome follow-up. A larger commitment should follow evidence that the bottleneck being funded is the bottleneck actually limiting appropriate access. This is an operating proposal, not a validated implementation standard.
The finance team should maintain two related views. A cash view tracks when treatment and support costs occur, when reimbursement arrives and when any rebate can be reconciled. A value view tracks net expenditure, clinical outcomes and the uncertainty of longer-term benefit. Conflating the two can make an affordable timing arrangement look like a proven economic return. Executive confidence should come from a feasible care pathway and auditable obligations, with remaining clinical and financial uncertainty displayed explicitly.
FROM EVIDENCE TO ALLOCATION
The operating and investment case
Proposed design by Azis R. Dabas. These decisions and evaluation criteria are not outcomes established by the cited studies.
- Decision
- Fund a treatment-pathway readiness assessment and a limited operational rollout before expanding specialized capacity or taking on additional contractual exposure.
- Accountable owner
- The relevant clinical service-line director and payer access lead, jointly sponsored by the CFO and supported by pharmacy, nursing, social work, legal and outcomes-data stewardship.
The delivery sequence
- Map clinically assessed referrals to contractual eligibility, treatment-center capacity and unresolved support needs.
- Define the covered episode, supportive-service responsibilities, expected payments and liquidity exposure.
- Create a patient-governed coordination record with named owners and documented clinical decisions.
- Complete treatment and longitudinal follow-up, then reconcile contractual outcomes and explain missing data.
The economics
Author-proposed financial model: expected net expenditure includes product, care delivery, ancillary support, monitoring and contract administration, less realizable contractual concessions. Model the timing of each payment separately and stress-test treatment volume, time to collection, noncompletion and outcome-reconciliation delays. A clinical benefit forecast requires therapy-specific evidence; no lifetime savings or cure assumption is imported from this financing review.
The measures that govern expansion
- Clinically appropriate referral-to-treatment completion
- Time spent at each access and capacity dependency
- Unmet support needs and patient-reported burden
- Cash exposure and days to collection
- Outcome follow-up completeness and successfully reconciled obligations
Stop or redesign when
Pause capacity expansion or new financial commitments when clinical readiness, patient support, required follow-up or payment responsibilities are unresolved. Preserve necessary care and existing obligations while correcting the failed assumption.
THE EVIDENCE LEDGER
What supports the argument
Study findings, policy requirements and market signals support different claims. Their boundaries remain visible.
[1] policy · 2026-09-30 (page last modified)
CGT (Cell and Gene Therapy Access) Model
- Design or status
- Official description of an active voluntary payment and access model
- Verified finding
- The initial sickle cell model uses CMS-negotiated outcomes-based agreements, includes defined fertility-preservation supports and describes state implementation, provider care and data responsibilities.
- Boundary
- The page states model aims and operational requirements. It is not a completed evaluation establishing improved outcomes, access or net savings.
[2] peer-reviewed · June 24, 2024
Challenges for gene therapy in the financial sustainability of health systems: a scoping review
- Design or status
- Scoping review; 10 included publications from 279 identified records; search through February 2023
- Verified finding
- The review maps subscription, outcomes-based and amortization strategies, with implementation barriers involving data systems, endpoints, regulation and administrative costs.
- Boundary
- The review describes mechanisms proposed or used across different systems; it does not establish their comparative effectiveness or validate current US contract outcomes.
[3] peer-reviewed · 2024-07 (journal issue)
Enhancing pediatric access to cell and gene therapies
- Design or status
- Perspective describing market failure and a proposed pediatric advanced-medicines organization
- Verified finding
- The authors discuss pediatric market constraints and propose a development and commercialization entity working with academic manufacturing partners.
- Boundary
- This is a proposed organizational response, not an evaluated program or a clinical effectiveness comparison. The university repository lists the July 2024 issue date; the precise online publication day was not confirmed here.
[4] market · February 24, 2026
BioMarin pulls hemophilia gene therapy Roctavian, taking $240M hit after divestiture efforts flounder
- Design or status
- Trade reporting on a product withdrawal and company financial disclosure
- Verified finding
- The report describes BioMarin's decision to withdraw Roctavian after unsuccessful efforts to find a qualified buyer.
- Boundary
- One company's commercial decision cannot establish the safety, clinical effectiveness or economic viability of other cell or gene therapies.
FOLLOW THE SOURCE
Sources and editorial method
Selected evidence was reviewed through October 7, 2026. Numbered references connect claims to their underlying records. Economic mechanisms and business cases are the author’s analysis unless a source is cited. The review is selective; publication dates retain the precision available in the source.
CGT (Cell and Gene Therapy Access) Model
Centers for Medicare & Medicaid Services. CMS Innovation Center. . policy.
Challenges for gene therapy in the financial sustainability of health systems: a scoping review
Hugo Ossandon, Nicolás Armijo, Constanza Vargas, Gabriela M. Repetto, Manuel Antonio Espinoza. Orphanet Journal of Rare Diseases. . peer-reviewed.
Enhancing pediatric access to cell and gene therapies
Crystal L. Mackall, Catherine M. Bollard, Nancy Goodman, Casey Carr, Rebecca Gardner, Rayne Rouce, Elena Sotillo, Rich Stoner, Fyodor D. Urnov, Alan S. Wayne, Julie Park, Donald B. Kohn. Nature Medicine. . peer-reviewed.
DOI: 10.1038/s41591-024-03035-1 · Primary verification record · Consensus paper record
BioMarin pulls hemophilia gene therapy Roctavian, taking $240M hit after divestiture efforts flounder
Zoey Becker. Fierce Pharma. . market.
Study authors retain credit for their work. Researcher affiliations and publisher names do not imply affiliation with or endorsement of this analysis.